<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1186/s12941-019-0319-8</query><apiKey>6b19ee21fe6a243741a528650f7c8997</apiKey><result><total>1</total><start>1</start><pageLength>1</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">12941</journal-id><journal-title-group><journal-title>Annals of Clinical Microbiology and Antimicrobials</journal-title><abbrev-journal-title abbrev-type="publisher">Ann Clin Microbiol Antimicrob</abbrev-journal-title></journal-title-group><issn pub-type="epub">1476-0711</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s12941-019-0319-8</article-id><article-id pub-id-type="manuscript">319</article-id><article-id pub-id-type="doi">10.1186/s12941-019-0319-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title xml:lang="en">A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant <italic>Acinetobacter baumannii</italic> infections in intensive care units with clinical and environmental features</article-title></title-group><contrib-group><contrib contrib-type="author" id="Au1"><name><surname>Boral</surname><given-names>Baris</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Unaldi</surname><given-names>Özlem</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Ergin</surname><given-names>Alper</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Durmaz</surname><given-names>Riza</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au5"><name><surname>Eser</surname><given-names>Özgen Köseoğlu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs1294101903198_cor5">e</xref></contrib><contrib contrib-type="author"><collab><institution>the Acinetobacter Study Group</institution><contrib-group><contrib contrib-type="author" id="Au6"><name><surname>Zarakolu</surname><given-names>Pinar</given-names></name></contrib><contrib contrib-type="author" id="Au7"><name><surname>Ersöz</surname><given-names>Gülden</given-names></name></contrib><contrib contrib-type="author" id="Au8"><name><surname>Kaya</surname><given-names>Ali</given-names></name></contrib><contrib contrib-type="author" id="Au9"><name><surname>Haciseyitoglu</surname><given-names>Demet</given-names></name></contrib><contrib contrib-type="author" id="Au10"><name><surname>Ak</surname><given-names>Öznur</given-names></name></contrib><contrib contrib-type="author" id="Au11"><name><surname>Gencer</surname><given-names>Serap</given-names></name></contrib><contrib contrib-type="author" id="Au12"><name><surname>Sarigüzel</surname><given-names>Fatma Mutlu</given-names></name></contrib><contrib contrib-type="author" id="Au13"><name><surname>Çelik</surname><given-names>İlhami</given-names></name></contrib><contrib contrib-type="author" id="Au14"><name><surname>Uyanik</surname><given-names>Muhammet Hamdullah</given-names></name></contrib><contrib contrib-type="author" id="Au15"><name><surname>Özden</surname><given-names>Kemalettin</given-names></name></contrib><contrib contrib-type="author" id="Au16"><name><surname>Acikgöz</surname><given-names>Ziya Cibali</given-names></name></contrib><contrib contrib-type="author" id="Au17"><name><surname>Guner</surname><given-names>Rahmet</given-names></name></contrib><contrib contrib-type="author" id="Au18"><name><surname>Akcali</surname><given-names>Alper</given-names></name></contrib><contrib contrib-type="author" id="Au19"><name><surname>Sener</surname><given-names>Alper</given-names></name></contrib><contrib contrib-type="author" id="Au20"><name><surname>Adiloglu</surname><given-names>Ali</given-names></name></contrib><contrib contrib-type="author" id="Au21"><name><surname>Bulut</surname><given-names>Cemal</given-names></name></contrib><contrib contrib-type="author" id="Au22"><name><surname>Yalinay</surname><given-names>Meltem</given-names></name></contrib><contrib contrib-type="author" id="Au23"><name><surname>Dizbay</surname><given-names>Murat</given-names></name></contrib><contrib contrib-type="author" id="Au24"><name><surname>Aydemir</surname><given-names>Söhret</given-names></name></contrib><contrib contrib-type="author" id="Au25"><name><surname>Sipahi</surname><given-names>Oguz Resat</given-names></name></contrib></contrib-group></collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2342 7339</institution-id><institution-id institution-id-type="GRID">grid.14442.37</institution-id><institution content-type="org-division">Department of Medical Microbiology</institution><institution content-type="org-name">Hacettepe University Faculty of Medicine</institution></institution-wrap><addr-line content-type="city">Ankara</addr-line><country country="TR">Turkey</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution content-type="org-division">Department of Microbiology Reference Laboratories</institution><institution content-type="org-name">National Molecular Microbiology Reference Laboratory</institution></institution-wrap><addr-line content-type="city">Ankara</addr-line><country country="TR">Turkey</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2342 7339</institution-id><institution-id institution-id-type="GRID">grid.14442.37</institution-id><institution content-type="org-name">Hacettepe University School of Health Services</institution></institution-wrap><addr-line content-type="city">Ankara</addr-line><country country="TR">Turkey</country></aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0454 9762</institution-id><institution-id institution-id-type="GRID">grid.449874.2</institution-id><institution content-type="org-division">Department of Medical Microbiology</institution><institution content-type="org-name">Ankara Yildirim Beyazit University Faculty of Medicine</institution></institution-wrap><addr-line content-type="city">Ankara</addr-line><country country="TR">Turkey</country></aff></contrib-group><author-notes><corresp id="IDs1294101903198_cor5"><label>e</label><phone>+90 312 3051560</phone><email>ozgen.eser@hacettepe.edu.tr</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>2</day><month>7</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2019</year></pub-date><volume>18</volume><issue seq="19">1</issue><elocation-id>19</elocation-id><history><date date-type="registration"><day>21</day><month>6</month><year>2019</year></date><date date-type="received"><day>13</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>21</day><month>6</month><year>2019</year></date><date date-type="online"><day>2</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s) 2019</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="url">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" ext-link-type="url">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1" xml:lang="en"><title>Abstract</title><sec id="ASec1"><title>Background</title><p id="Par1">Multidrug-resistant (MDR) <italic>Acinetobacter baumannii</italic> infections are considered as emerging nosocomial infections particularly in patients hospitalized in intensive care units (ICUs). Therefore, reliable detection of MDR strains is crucial for management of treatment but also for epidemiological data collections. The purpose of this study was to compare antimicrobial resistance and the clonal distribution of MDR clinical and environmental <italic>A</italic>. <italic>baumannii</italic> isolates obtained from the ICUs of 10 different hospitals from five geographical regions of Turkey in the context of the demographic and clinical characteristics of the patients.</p></sec><sec id="ASec2"><title>Methods</title><p id="Par2">A multicenter-prospective study was conducted in 10 medical centers of Turkey over a 6 month period. A total of 164 clinical and 12 environmental MDR <italic>A. baumannii</italic> isolates were included in the study. Antimicrobial susceptibility testing was performed for amikacin (AN), ampicillin–sulbactam (SAM), ceftazidime (CAZ), ciprofloxacin (CIP), imipenem (IMP) and colistin (COL) by microdilution method and by antibiotic gradient test for tigecycline (TIG). Pulsed-field gel electrophoresis (PFGE) was performed to determine the clonal relationship between the isolates. The detection of the resistance genes, <italic>bla</italic><sub>OXA-23</sub>, <italic>bla</italic><sub>OXA-24</sub>, <italic>bla</italic><sub>OXA-51,</sub><italic>bla</italic><sub>OXA-58,</sub><italic>bla</italic><sub>IMP,</sub><italic>bla</italic><sub>NDM</sub>, <italic>bla</italic><sub>KPC</sub>, <italic>bla</italic><sub>OXA-48</sub> and <italic>bla</italic><sub>PER-1</sub> was carried out using the PCR method.</p></sec><sec id="ASec3"><title>Results</title><p id="Par3">The mortality rate of the 164 patients was 58.5%. The risk factors for mortality included diabetes mellitus, liv1er failure, the use of chemotherapy and previous use of quinolones. Antimicrobial resistance rates for AN, SAM, CAZ, CIP, IMP, COL and TIG were 91.8%, 99.4%, 99.4%, 100%, 99.4%, 1.2% and 1.7% respectively. Colistin showed the highest susceptibility rate. Four isolates did not grow on the culture and were excluded from the analyses. Of 172 isolates, 166 (96.5%) carried <italic>bla</italic><sub>OXA-23</sub>, 5 (2.9%) <italic>bla</italic><sub>OXA-58</sub> and one isolate (0.6%) was positive for both genes. The frequency of <italic>bla</italic><sub>PER-1</sub> was found to be 2.9%. None of the isolates had <italic>bla</italic><sub>IMP</sub>, <italic>bla</italic><sub>KPC</sub>, <italic>bla</italic><sub>NDM</sub> and <italic>bla</italic><sub>OXA-48</sub> genes. PFGE analysis showed 88 pulsotypes. Fifteen isolates were clonally unrelated. One hundred fifty-seven (91.2%) of the isolates were involved in 14 different clusters.</p></sec><sec id="ASec4"><title>Conclusions</title><p id="Par4">Colistin is still the most effective antibiotic for <italic>A</italic>. <italic>baumannii</italic> infections. The gene <italic>bla</italic><sub>OXA-23</sub> has become the most prevalent carbapenemase in Turkey. The distribution of invasive <italic>A</italic>. <italic>baumannii</italic> isolates from different regions of Turkey is not diverse so, infection control measures at medical centers should be revised to decrease the MDR <italic>A. baumannii</italic> infections across the country. The results of this study are expected to provide an important baseline to assess the future prophylactic and therapeutic options.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>Acinetobacter baumannii</italic></kwd><kwd>Risk factors</kwd><kwd>Antimicrobial resistance genes</kwd><kwd>Polymerase chain reaction</kwd><kwd>Pulsed field gel electrophoresis</kwd><kwd>Clonal relatedness</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Hacettepe Üniversitesi</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/501100005378</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">011 D07 101 007-135</award-id><principal-award-recipient><name><surname>Eser</surname><given-names>Özgen Köseoğlu</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>BioMed Central</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>No</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>6</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>21</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/12941_2019_Article_319.pdf</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Biomedicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Medical Microbiology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Infectious Diseases</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Drug Resistance</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Microbial Genetics and Genomics</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Biochemistry, general</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Parasitology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Biomedical and Life Sciences</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par5">Invasive infections due to <italic>Acinetobacter baumannii</italic> are among the leading nosocomial infections in patients hospitalized in intensive care unit (ICU) [<xref ref-type="bibr" rid="CR1">1</xref>]. The increasing number of these infections and the emergence of multidrug-resistant (MDR) strains make <italic>A</italic>. <italic>baumannii</italic> a troublesome pathogen especially in a hospital environment [<xref ref-type="bibr" rid="CR1">1</xref>]. <italic>A. baumannii</italic> accounts for almost 90% of all reported <italic>Acinetobacter</italic> infections including ventilator-associated pneumonia, bacteremia, meningitis, peritonitis, urinary tract infections and wound infections [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par6">Hospital-acquired pneumonia represents the most common clinical manifestation of <italic>A</italic>. <italic>baumannii</italic> infections. <italic>A. baumannii</italic> is also a common cause of bloodstream infections in ICUs [<xref ref-type="bibr" rid="CR3">3</xref>]. The most common sources of these infections are the patients having lower respiratory tract infections and intravascular devices [<xref ref-type="bibr" rid="CR4">4</xref>]. Risk factors include immunosuppression, ventilator- associated respiratory failure, previous antibiotic therapy, colonization with <italic>A</italic>. <italic>baumannii</italic> and invasive procedures [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par7">Initial effective treatment is key to increasing the survival rate in bacterial infectious diseases however providing such treatment is a major clinical challenge due to the high rate of antibiotic resistance. For instance, increasing carbapenem resistance in <italic>A</italic>. <italic>baumannii</italic> infections is a serious threat for causing a rise in healthcare costs and worsening clinical outcome. The main mechanism of carbapenem resistance in <italic>A. baumannii</italic> is hydrolysis of carbapenems with metallo-beta-lactamases and/or class D beta lactamases. Although metallo-beta-lactamases (VIM, IMP, SIM) have been reported especially in Asia and Western Europe, class D beta-lactamases (OXA-23, OXA-24 or -40, OXA-51, OXA-58, and OXA-143) have been identified in the United States, Latin America, Europe, Asia and many other parts of the world [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Studies of the class D beta-lactamases show that especially the <italic>bla</italic><sub>OXA-23</sub> gene can be easily spread via transposons and conjugative plasmids [<xref ref-type="bibr" rid="CR8">8</xref>]. The successful evolution of transposons bearing the <italic>bla</italic><sub>OXA-23</sub> resistance gene has an important role in spreading the resistant bacteria worldwide [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par8">Various genotyping methods such as ribotyping, pulsed-field gel electrophoresis (PFGE), multilocus sequence typing (MLST), single locus sequence typing (SLST), and analysis of restriction fragment length polymorphism (RFLP) can be used to understand transmission dynamics of MDR <italic>A</italic>. <italic>baumannii</italic>. The PFGE technique is known as the gold standard for genotyping of <italic>A</italic>. <italic>baumannii</italic> strains [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par9">Epidemiological studies on the clinical and molecular characteristics of <italic>A</italic>. <italic>baumannii</italic> strains might help to determine infection control strategies for different centers. The purpose of this study was to evaluate antimicrobial drug resistance mechanisms and the clonal distribution of clinical and environmental MDR <italic>A</italic>. <italic>baumannii</italic> isolates from ICUs in five geographical regions of Turkey and to compare these with the demographic characteristics of the patients.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par10">A prospective multicenter study was conducted from 10 different medical centers located in five different geographical regions (Aegean, Central and Eastern Anatolia, Marmara, Mediterranean) of Turkey in 2012. All patients who were admitted to the ICUs of medical centers with the diagnosis of invasive <italic>A</italic>. <italic>baumannii</italic> infections were included in the study. The study was reviewed and approved by the Non-Interventional Clinical Research Ethics Committee of Hacettepe University, Ankara, Turkey.</p></sec><sec id="Sec4"><title>Patient characteristics and risk factors</title><p id="Par11">The characteristics and risk factors of 164 patients with clinical and microbiological diagnosis of <italic>A</italic>. <italic>baumannii</italic> were analyzed. Data were collected prospectively in a standardized case report form. The following data were recorded in all centers: age, gender, occupation, immunosuppression, underlying diseases, previous hospitalization, duration of stay in the unit, invasive procedures or surgery within 30 days before the diagnosis, prior antibiotic treatment and outcome of treatment. Invasive procedures included central and urinary catheterization, mechanical ventilation, nasogastric tube placement, and orotracheal intubation.</p></sec><sec id="Sec5"><title>Sample collection and identification of the isolates</title><p id="Par12">A total of 164 clinical and 12 environmental <italic>A</italic>. <italic>baumannii</italic> isolates were included in the study. The participating centers were Hacettepe University Hospitals (HACET) (Center 1), Gazi University Hospital (GAZI) (Center 2), Ankara Education and Research Hospital (AH) (Center 3), Ankara Ataturk Education and Research Hospital (AEH) (Center 4), Kayseri Education and Research Hospital (KEAH) (Center 5), Canakkale Onsekiz Mart University Hospital (Center 6), Dr. Lutfu Kirdar Education and Research Hospital (Center 7), Ataturk University, Research Hospital (Center 8), Ege University Hospital (Center 9) and Mersin University Hospital (Center 10) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). All the patients had monomicrobial infection with MDR <italic>A. baumannii</italic>. Clinical isolates were obtained from patients hospitalized in medicine and surgery ICUs, with samples taken from blood (89%) and other sterile body sites [cerebrospinal fluid (CSF), bronchoalveolar lavage fluid (BAL), pleural fluid, tissue and catheter]. Environmental isolates were taken from table surfaces, sinks, taps and pumps from the ICUs in all centers.<fig id="Fig1"><label>Fig. 1</label><caption xml:lang="en"><p>Distribution of centers collaborating in the study</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/12941_2019_319_Fig1_HTML.png" id="MO1"/></p></fig></p><p id="Par13">All isolates were identified by automated systems [either the Vitek 2 system (bioMérieux, Marcy-l’Étoile, France) or Phoenix system (Becton–Dickinson, Franklin Lakes, NJ)] and they were confirmed at Hacettepe University Faculty of Medicine, Department of Medical Microbiology by conventional methods and also by molecular methods for confirming the existence of the <italic>bla</italic><sub>OXA-51</sub> gene. All the confirmed isolates were kept at − 80 °C during the data collection period.</p></sec><sec id="Sec6"><title>Antimicrobial susceptibility testing</title><p id="Par14">Antimicrobial susceptibility tests were performed for six antimicrobials; ampicillin–sulbactam (SAM), amikacin (AN), ceftazidime (CAZ), ciprofloxacin (CIP), imipenem (IMP) and colistin (COL) by using the broth microdilution method according to Clinical Laboratory Standards Institute (CLSI) guidelines [<xref ref-type="bibr" rid="CR10">10</xref>]. <italic>Pseudomonas aeruginosa</italic> ATCC 27853 strain was used as a reference control in all antibiotic susceptibility testings except for sulbactam–ampicillin. <italic>Escherichia coli</italic> ATCC 35218 was used as a reference control for this antibiotic. In addition, the minimal inhibitory concentration (MIC) value for tigecycline (TIG) was determined by antibiotic gradient strips, Etest (bioMérieux, France). Interpretation break points for TIG of ≤ 1 mg/L were considered as susceptible, and ≥ 4 mg/L as resistant and MIC values against tigecycline were evaluated using FDA-approved breakpoints provided in the package insert [<xref ref-type="bibr" rid="CR11">11</xref>].</p></sec><sec id="Sec7"><title>Detection of antibiotic resistance genes</title><p id="Par15">Two multiplex PCR protocols were carried out for the detection of resistance genes; one for <italic>bla</italic><sub>OXA-23</sub>, <italic>bla</italic><sub>OXA-24</sub>, <italic>bla</italic><sub>OXA-51,</sub> and <italic>bla</italic><sub>OXA-58</sub> and the other one for <italic>bla</italic><sub>IMP</sub>, <italic>bla</italic><sub>NDM</sub>, <italic>bla</italic><sub>KPC</sub>, <italic>bla</italic><sub>OXA-48</sub> in all 172 isolates [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The existence of the <italic>bla</italic><sub>PER-1</sub> gene was also determined by using a protocol which was described by Weldhagen et al. [<xref ref-type="bibr" rid="CR14">14</xref>]. Each PCR reaction (25 μL) contained 12.5 μL of Taq PCR master mix (New England Biolabs, Beverly, MA), 5.5 μL sterile-RNase free water, 0.5 μL of each primer (100 μM, final concentration 2 μM) and 2 μL of DNA template. Amplified products were visualized on 2% agarose gel.</p></sec><sec id="Sec8"><title>Pulsed-field gel electrophoresis</title><p id="Par16">PFGE of 172 isolates was implemented as previously described by Durmaz et al. [<xref ref-type="bibr" rid="CR15">15</xref>]. Briefly, the genomic DNA was digested with <italic>Apa</italic>I (New England Biolabs, Beverly, MA). The plugs were embedded into 1% agarose gel wells. Subsequently, the separation of the DNA bands was carried out using the CHEF DR III system (Bio-Rad, Nazareth, Belgium) at 6 V/cm<sup>2</sup> for 19 h and the pulse time was changed from 5 to 20 s. PFGE pattern analysis was carried out by using Bionumerics software version 4.0 (Applied Maths, Austin, TX) and with the unweighted-pair group method using average linkages. In order to analyze clusters Dice settings were used.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par17">Univariate conditional logistic regressions were used in the study group. Odds ratios were estimated by exponentiation of regression coefficients and their 95% confidence interval (CIs) reported. To adjust for confounding factors, variables with a <italic>p</italic> value below the 10% significance level in univariate analysis were entered in multiple conditional logistic regression models.</p></sec></sec><sec id="Sec10" sec-type="results"><title>Results</title><sec id="Sec11"><title>Patient characteristics and risk factors</title><p id="Par18">A total of 164 patients were included in the study. Of these patients, 88 (53.6%) were men and the age range was 15 days–78 years. The mean age of the patients was 60.1. Data from all 164 patients indicated that 52.4% of them were hospitalized in surgical ICUs, 30.5% in medical ICUs, 11% in burns units and 6.1% in emergency medicine service (Table <xref rid="Tab1" ref-type="table">1</xref>). At least one underlying disease was identified in 95% of the patients. The most frequent diagnosis was ventilator-associated pneumonia (VAP) (26.6%) followed by malignancy (23%). The underlying diseases of patients were recorded as diabetus mellitus (DM), chronic kidney failure (CKF), chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), chronic liver failure (CLF) and febrile neutropenia (FEN). The risk factors for mortality contained DM [hazard ratio (HR): 2.74; <italic>p </italic>= 0.026], CLF (HR: 4.27; <italic>p </italic>= 0.047), chemotherapy (HR: 3.69; <italic>p </italic>= 0.03) and previous usage of fluoroquinolones (HR: 3.64; <italic>p </italic>= 0.01) (Table <xref rid="Tab2" ref-type="table">2</xref>). According to available data, carbapenems (67/153) and third generation cephalosporins (51/153) were the most common antibiotics received by patients before the diagnosis of MDR <italic>A</italic>. <italic>baumannii</italic> infection.<table-wrap id="Tab1"><label>Table 1</label><caption xml:lang="en"><p>The demographic features of the patients and risk factors (n = 164)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><p>Number (<italic>n</italic>)</p></th><th align="left"><p>Frequency (<italic>%</italic>)</p></th></tr></thead><tbody><tr><td align="left" colspan="3"><p>Gender</p></td></tr><tr><td align="left"><p> Male</p></td><td align="left"><p>88</p></td><td align="left"><p>53.6</p></td></tr><tr><td align="left"><p> Female</p></td><td align="left"><p>76</p></td><td align="left"><p>46.3</p></td></tr><tr><td align="left" colspan="3"><p>Service</p></td></tr><tr><td align="left"><p> Medical ICUs</p></td><td align="left"><p>50</p></td><td align="left"><p>30.5</p></td></tr><tr><td align="left"><p> Surgical ICUs</p></td><td align="left"><p>86</p></td><td align="left"><p>52.4</p></td></tr><tr><td align="left"><p> Burn ICUs</p></td><td align="left"><p>18</p></td><td align="left"><p>11</p></td></tr><tr><td align="left"><p> Emergency service</p></td><td align="left"><p>10</p></td><td align="left"><p>6.1</p></td></tr><tr><td align="left" colspan="3"><p>Immunosuppression</p></td></tr><tr><td align="left"><p> Corticosteroid usage</p></td><td align="left"><p>18</p></td><td align="left"><p>11</p></td></tr><tr><td align="left"><p> Transplantation (solid organ, bone marrow)</p></td><td align="left"><p>–</p></td><td align="left"><p>–</p></td></tr><tr><td align="left"><p> Chemotherapy</p></td><td align="left"><p>15</p></td><td align="left"><p>9.1</p></td></tr><tr><td align="left" colspan="3"><p>Invasive procedures</p></td></tr><tr><td align="left"><p> Central catheterisation</p></td><td align="left"><p>125</p></td><td align="left"><p>76.2</p></td></tr><tr><td align="left"><p> Urinary catheterisation</p></td><td align="left"><p>161</p></td><td align="left"><p>98.2</p></td></tr><tr><td align="left"><p> Mechanical ventilation</p></td><td align="left"><p>112</p></td><td align="left"><p>68.7</p></td></tr><tr><td align="left"><p> Nasogastric tube</p></td><td align="left"><p>86</p></td><td align="left"><p>52.4</p></td></tr><tr><td align="left"><p> Orotracheal intubation</p></td><td align="left"><p>74</p></td><td align="left"><p>45.4</p></td></tr><tr><td align="left"><p> Other</p></td><td align="left"><p>32</p></td><td align="left"><p>19.5</p></td></tr><tr><td align="left"><p>Mortality</p></td><td align="left"><p>96</p></td><td align="left"><p>58.5</p></td></tr></tbody></table><table-wrap-foot><p><italic>ICU</italic> intensive care unit</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption xml:lang="en"><p>The risk factors of mortality among patients (n = 164)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2"><p>Mortality</p><p>(<italic>n </italic>= 96)</p></th><th align="left" rowspan="2"><p>Survival (<italic>n </italic>= 68)</p></th><th align="left" colspan="2"><p>Univariate analysis</p></th></tr><tr><th align="left"><p>Risk ratio (%95 CI)</p></th><th align="left"><p><italic>p</italic> value</p></th></tr></thead><tbody><tr><td align="left" colspan="5"><p>Demographic features</p></td></tr><tr><td align="left"><p> Age</p></td><td align="left"/><td align="left"/><td char="(" align="char"><p>1.863 (1.251–2.775)</p></td><td char="." align="char"><p><italic>0.001</italic></p></td></tr><tr><td align="left"><p>  &lt; 64</p></td><td char="." align="char"><p>39</p></td><td char="." align="char"><p>45</p></td><td align="left"/><td align="left"/></tr><tr><td align="left"><p>  &gt; 65</p></td><td char="." align="char"><p>57</p></td><td char="." align="char"><p>23</p></td><td align="left"/><td align="left"/></tr><tr><td align="left"><p> Gender</p></td><td align="left"/><td align="left"/><td char="(" align="char"><p>1.380 (0.0939–2.028)</p></td><td char="." align="char"><p>0.093</p></td></tr><tr><td align="left"><p>  Male</p></td><td char="." align="char"><p>48</p></td><td char="." align="char"><p>43</p></td><td char="(" align="char"/><td char="." align="char"/></tr><tr><td align="left"><p>  Female</p></td><td char="." align="char"><p>48</p></td><td char="." align="char"><p>25</p></td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" colspan="5"><p> Comorbidity</p></td></tr><tr><td align="left"><p>  Diabetes mellitus</p></td><td char="." align="char"><p>23</p></td><td char="." align="char"><p>7</p></td><td char="(" align="char"><p>2.746 (1.103–6.833)</p></td><td char="." align="char"><p><italic>0.026</italic></p></td></tr><tr><td align="left"><p>  Chronic obstructive pulmonary diseases</p></td><td char="." align="char"><p>12</p></td><td char="." align="char"><p>6</p></td><td char="(" align="char"><p>1.476 (0.525–4.149)</p></td><td char="." align="char"><p>0.458</p></td></tr><tr><td align="left"><p>  Congestive heart failure</p></td><td char="." align="char"><p>12</p></td><td char="." align="char"><p>8</p></td><td char="(" align="char"><p>1.071 (0.413–2.781)</p></td><td char="." align="char"><p>0.887</p></td></tr><tr><td align="left"><p>  Chronic liver failure</p></td><td char="." align="char"><p>11</p></td><td char="." align="char"><p>2</p></td><td char="(" align="char"><p>4.271 (0.915–19.932)</p></td><td char="." align="char"><p><italic>0.047</italic></p></td></tr><tr><td align="left"><p>  Corticosteroid usage</p></td><td char="." align="char"><p>8</p></td><td char="." align="char"><p>11</p></td><td char="(" align="char"><p>0.471 (0.179–1.242)</p></td><td char="." align="char"><p>0.122</p></td></tr><tr><td align="left"><p>  Neutropenia</p></td><td char="." align="char"><p>4</p></td><td char="." align="char"><p>2</p></td><td char="(" align="char"><p>1.435 (0.255–8.065)</p></td><td char="." align="char"><p>0.680</p></td></tr><tr><td align="left"><p>  Malignancy</p></td><td char="." align="char"><p>27</p></td><td char="." align="char"><p>12</p></td><td char="(" align="char"><p>1.826 (0.849–3.924)</p></td><td char="." align="char"><p>0.120</p></td></tr><tr><td align="left"><p>  Chemotherapy</p></td><td char="." align="char"><p>14</p></td><td char="." align="char"><p>3</p></td><td char="(" align="char"><p>3.699 (1.020–13.421)</p></td><td char="." align="char"><p><italic>0.035</italic></p></td></tr><tr><td align="left" colspan="5"><p> Invasive procedures</p></td></tr><tr><td align="left"><p>  Mechanical ventilation</p></td><td char="." align="char"><p>67</p></td><td char="." align="char"><p>38</p></td><td char="(" align="char"><p>1.824 (0.955–3.484)</p></td><td char="." align="char"><p>0.067</p></td></tr><tr><td align="left"><p>  Central catheterisation</p></td><td char="." align="char"><p>74</p></td><td char="." align="char"><p>54</p></td><td char="(" align="char"><p>0.872 (0.409–1.858)</p></td><td char="." align="char"><p>0.723</p></td></tr><tr><td align="left"><p>  Urinary catheterisation</p></td><td char="." align="char"><p>94</p></td><td char="." align="char"><p>66</p></td><td char="(" align="char"><p>1.424 (0.196–10.368)</p></td><td char="." align="char"><p>0.726</p></td></tr><tr><td align="left" colspan="5"><p> Drugs used before diagnosis</p></td></tr><tr><td align="left"><p>  Penicillin and derivatives</p></td><td char="." align="char"><p>29</p></td><td char="." align="char"><p>15</p></td><td char="(" align="char"><p>1.529 (0.744–3.142)</p></td><td char="." align="char"><p>0.246</p></td></tr><tr><td align="left"><p>  3rd generation cephalosporins</p></td><td char="." align="char"><p>32</p></td><td char="." align="char"><p>23</p></td><td char="(" align="char"><p>1.067 (0.542–2.099)</p></td><td char="." align="char"><p>0.852</p></td></tr><tr><td align="left"><p>  Fluoroquinolones</p></td><td char="." align="char"><p>22</p></td><td char="." align="char"><p>5</p></td><td char="(" align="char"><p>3.646 (1.30–10.227)</p></td><td char="." align="char"><p><italic>0.010</italic></p></td></tr><tr><td align="left"><p>  Aminoglycosides</p></td><td char="." align="char"><p>7</p></td><td char="." align="char"><p>2</p></td><td char="(" align="char"><p>2.512 (0.504–12.510)</p></td><td char="." align="char"><p>0.246</p></td></tr><tr><td align="left"><p>  Carbapenems</p></td><td char="." align="char"><p>49</p></td><td char="." align="char"><p>37</p></td><td char="(" align="char"><p>0.840 (0.438–1.610)</p></td><td char="." align="char"><p>0.599</p></td></tr><tr><td align="left"><p>  Colistin</p></td><td char="." align="char"><p>3</p></td><td char="." align="char"><p>5</p></td><td char="(" align="char"><p>0.391 (0.090–1.699)</p></td><td char="." align="char"><p>0.196</p></td></tr></tbody></table><table-wrap-foot><p>The value of <italic>p</italic> &lt; 0.05 was set as the significance threshold (in italics)</p><p><italic>CI</italic> confidence interval</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Antimicrobial susceptibility testing</title><p id="Par19">The antimicrobial susceptibility test results of the 160 clinical and 12 environmental <italic>A</italic>. <italic>baumannii</italic> isolates were shown in Table <xref rid="Tab3" ref-type="table">3</xref>. Four clinical isolates could not be regenerated during the study. A high proportion of the isolates were resistant to AN (91.8%), SAM (99.4%), CAZ (99.4%), CIP (100%) and IMP (99.4%) while most isolates were susceptible to COL (98.8%) and TIG (98.3%). Strains were considered as multidrug-resistant when the resistance was detected for at least one agent in three or more different categories of antimicrobials according to the definition of Magiorakos et al. [<xref ref-type="bibr" rid="CR16">16</xref>].<table-wrap id="Tab3"><label>Table 3</label><caption xml:lang="en"><p>Antimicrobial susceptibility of invasive MDR <italic>A. baumannii</italic> isolates from ICUs (<italic>n </italic>= 172)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Antimicrobial agent</p></th><th align="left"><p>MIC<sub>50</sub> (mg/L)</p></th><th align="left"><p>MIC<sub>90</sub> (mg/L)</p></th><th align="left"><p>MIC range (mg/L)</p></th><th align="left"><p>Resistance (%)</p></th></tr></thead><tbody><tr><td align="left"><p>Amikacin</p></td><td align="left"><p>≥ 256</p></td><td align="left"><p>≥ 256</p></td><td align="left"><p>1 to  ≥ 256</p></td><td char="." align="char"><p>91.8</p></td></tr><tr><td align="left"><p>Ampicillin–sulbactam</p></td><td align="left"><p>256</p></td><td align="left"><p>≥ 256</p></td><td align="left"><p>32 to  ≥ 256</p></td><td char="." align="char"><p>99.4</p></td></tr><tr><td align="left"><p>Ceftazidime</p></td><td align="left"><p>256</p></td><td align="left"><p>≥ 256</p></td><td align="left"><p>16 to  ≥ 256</p></td><td char="." align="char"><p>99.4</p></td></tr><tr><td align="left"><p>Ciprofloxacin</p></td><td align="left"><p>128</p></td><td align="left"><p>≥ 256</p></td><td align="left"><p>8 to  ≥ 256</p></td><td char="." align="char"><p>100</p></td></tr><tr><td align="left"><p>Imipenem</p></td><td align="left"><p>64</p></td><td align="left"><p>128</p></td><td align="left"><p>1 to  ≥ 256</p></td><td char="." align="char"><p>99.4</p></td></tr><tr><td align="left"><p>Colistin</p></td><td align="left"><p>0.5</p></td><td align="left"><p>1.0</p></td><td align="left"><p>0.25–64</p></td><td char="." align="char"><p>1.2</p></td></tr><tr><td align="left"><p>Tigecycline</p></td><td align="left"><p>1.0</p></td><td align="left"><p>2.0</p></td><td align="left"><p>0.01–3</p></td><td char="." align="char"><p>1.7</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec13"><title>Detection of antibiotic resistance genes</title><p id="Par20">All <italic>A</italic>. <italic>baumannii</italic> isolates possessed <italic>bla</italic><sub>OXA-51</sub> gene. The <italic>bla</italic><sub>OXA-23</sub> gene was detected in 166/172 (96%) isolates while <italic>bla</italic><sub>OXA-58</sub> was detected only in 5/172 (3%) isolates and none of the isolates had <italic>bla</italic><sub>OXA-24</sub> gene. One isolate carried both <italic>bla</italic><sub>OXA-23</sub> and <italic>bla</italic><sub>OXA-58</sub> genes. The <italic>bla</italic><sub>OXA-23</sub> was detected in all centers whereas <italic>bla</italic><sub>OXA-58</sub> gene was detected only in Center 5. The <italic>bla</italic><sub>PER-1</sub> gene was detected from three centers; Center 9 (<italic>n </italic>= 2), Center 10 (<italic>n </italic>= 2) and Center 7 (<italic>n </italic>= 1). None of the isolates showed <italic>bla</italic><sub>IMP</sub>, <italic>bla</italic><sub>KPC</sub>, <italic>bla</italic><sub>NDM</sub>, and <italic>bla</italic><sub>OXA-48</sub> genes (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption xml:lang="en"><p>The frequency of resistance genes according to centers</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/12941_2019_319_Fig2_HTML.png" id="MO2"/></p></fig></p></sec><sec id="Sec14"><title>Molecular epidemiology</title><p id="Par21">PFGE typing of the 172 isolates revealed 88 pulsotypes. Twenty-nine of these pulsotypes included two or more strains which could not be differentiated from each other. Totally 98 strains were classified in 29 pulsotypes, the clustering rate was 57%. When the similarity rate between the pulsotypes was assigned as ≥ 85%, 157 clonally related strains (91.2%) were clustered in 14 PFGE groups (I-XIV). Group VI (<italic>n </italic>= 27) was the largest among the PFGE groups followed by the groups II (<italic>n </italic>= 24) and IX (<italic>n </italic>= 21). Since dendrogram of all pulsotypes was very large, a cross-sectional example of dendrogram representing the most common PFGE group was shown as Fig. <xref rid="Fig3" ref-type="fig">3</xref>. Evaluation of the PFGE group types according to the centers revealed that group VI was dominant in three centers (Center 3, Center 4, and Center 5) and was the second most dominant type in two centers (Center 1 and Center 2). The clinical (<italic>n </italic>= 10) and environmental (<italic>n </italic>= 2) isolates recovered from different ICUs of Center 6 were in the PFGE group IV and these isolates were all identical. In five centers located in Central Anatolia, group VI was the dominant group. Group II was detected more often in two centers (Center 9 and Center 10). In group XII, isolates were only from Center 7, and 11 of these isolates were obtained from the burns unit. Center 8 differed from the other centers since the dominant group type was XIV for this center.<fig id="Fig3"><label>Fig. 3</label><caption xml:lang="en"><p>A cross-sectional example of PFGE dendogram representing the largest PFGE group (Group VI, <italic>n </italic>= 27). PFGE types; the strains having indistinguishable DNA band profile were clustered in the same PFGE types and labeled with a same number such as PFGE type 42 included 3 stains, any difference in PFGE patterns was defined as unique and labeled with different number. PFGE group VI included the strains having PFGE patterns that were similar to each other ≥ 85%</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/12941_2019_319_Fig3_HTML.png" id="MO3"/></p></fig></p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p id="Par22"><italic>Acinetobacter baumannii</italic> has become one of the most serious threats especially in the ICUs of the hospitals being respondless to antibiotic therapy. Therefore, new strategies should be adopted to combat this pathogen. At this point, data obtained from especially multicenter studies is needed to understand the epidemiology of <italic>A</italic>. <italic>baumannii</italic>. The examination of demographic characteristics of patients with MDR <italic>A</italic>. <italic>baumannii</italic> infections, detection of resistance genes and the spread of resistant strains in hospitals can help to control these infection. In this study, epidemiological characteristics of invasive <italic>A</italic>. <italic>baumannii</italic> strains from 10 medical centers in five different geographical regions of Turkey were evaluated. To our knowledge, the current study is the most comprehensive epidemiological study in Turkey in terms of distribution and number of participant centers and isolates.</p><p id="Par23">The important risk factors for mortality in patients with <italic>A</italic>. <italic>baumannii</italic> infections were long-term medication in ICUs, APACHE II score &gt; 20, ventilator associated bacteremia, use of third generation cephalosporins before the diagnosis of infection and liver cirrhosis [<xref ref-type="bibr" rid="CR17">17</xref>]. In our study, being &gt; 65 age, having DM or CLF, taking chemotherapeutic drugs or fluoroquinolones before diagnosis were found to be related with mortality. On the contrary, using carbapenem or third generation cephalosporins was not found to be related to mortality in the studied patient population.</p><p id="Par24">According to surveillance studies, carbapenem resistance is a major problem in the treatment of <italic>A</italic>. <italic>baumannii</italic> infections especially in Turkey, Greece, Italy, Spain, Romania and the UK [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In our study, colistin was the most effective antimicrobial agent against MDR <italic>A. baumannii</italic> isolates, confirming the multicenter study which SENTRY performed between 2001 and 2011 and it was reported that colistin had low level resistance (0.9–3.3%) and was still effective against MDR <italic>A</italic>. <italic>baumannii</italic> isolates [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par25">Among the resistance genes responsible for carbapenem resistance in <italic>A</italic>. <italic>baumannii</italic> isolates, <italic>bla</italic><sub>OXA-23</sub>, <italic>bla</italic><sub>OXA-24</sub> and <italic>bla</italic><sub>OXA-58</sub> are the top leading ones. The dominance of these genes in resistant <italic>A</italic>. <italic>baumannii</italic> isolates has been changed all over the world. The predominance of <italic>bla</italic><sub>OXA-58</sub> between 1999 and 2009 in Mediterranean countries like Italy, Greece, Lebanon and Turkey has showed a transition to <italic>bla</italic><sub>OXA-23</sub> since 2009 causing an increase in the frequency of <italic>bla</italic><sub>OXA-23</sub>. This rise caused of a higher carbapenem MIC<sub>50</sub> and MIC<sub>90</sub> values between 2010 (16 mg/L and 256 mg/L, respectively) and 2011 (128 mg/L and 256 mg/L) [<xref ref-type="bibr" rid="CR20">20</xref>]. There are some reports about the rise of <italic>bla</italic><sub>OXA-23</sub> gene in carbapenem resistant strains of <italic>A</italic>. <italic>baumannii</italic> in Turkey [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Although the study populations and duration time of these studies had some differences, there was a consensus about the increasing number of MDR <italic>A</italic>. <italic>baumannii</italic> isolates which have <italic>bla</italic><sub>OXA-23</sub> gene. As the <italic>bla</italic><sub>OXA-23</sub> enzyme was found in all centers but <italic>bla</italic><sub>OXA-58</sub> only in one center, the results of the current study highlighted that <italic>bla</italic><sub>OXA-23</sub> gene is the most prevalent oxacillinase in Turkey.</p><p id="Par26">The frequency of <italic>bla</italic><sub>PER-1</sub> can vary from country to country. In Turkey according to the local studies, the frequency of <italic>bla</italic><sub>PER-1</sub> among MDR <italic>A</italic>. <italic>baumannii</italic> isolates has been in a declining trend (52.9% to 8.3%) since 2008. In our study, the frequency of <italic>bla</italic><sub>PER-1</sub> was found to be 2.8%. According to previous reports, the annual rate of PER-1 detection decreased gradually over time and the most prominent decrease occurred in 2010 in Turkey. The frequency of PER-1 type β-lactamases in <italic>A. baumannii</italic> species has decreased, and PER-1 is no longer a threat in Turkey’s resistance profile [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par27">The important feature in the surveillance of MDR <italic>A</italic>. <italic>baumannii</italic> isolated from patients with hospital infections is the typing of strains by using a standard method such as PFGE. The use of PFGE especially in multicenter studies is very important to estimate the clonal relatedness between isolates obtained from different centers. A previous study revealed that 60‒80% of the strains were clonally related throughout the country [<xref ref-type="bibr" rid="CR24">24</xref>]. In the current study, the PFGE results of the clinical and environmental MDR <italic>A</italic>. <italic>baumannii</italic> strains isolated from the ICUs of Center 6, Center 7 and Center 10 revealed the same pulsotype although the regions of these centers are far away from each other. Furthermore, one of the clinical isolates of Center 10 was identical to the environmental isolate of Center 2, which is quite interesting since the regions are also far away from each other.</p><p id="Par28">Some of the strains which were responsible for mini epidemics in ICUs of different centers showed the same pulsotype profile with 91.2% relatedness and this result revealed that these isolates did not differ so much from each other. Detection of the same or very similar pulsotypes from different centers suggests that infection control measures should be strengthened and revised in our country. This situation can be achieved with the measures indicated in the report of Cheon et al. which described the control of endemic MDR <italic>A</italic>. <italic>baumannii</italic> outbreaks in ICUs within 1 year with comprehensive and intensive infection control measures such as effective antibiotic management, personnel training, contact precautions, hand hygiene and active surveillance cultures of hospital environmental samples [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par29">The current study also has some limitations. Although ten centers from five different regions of Turkey were included in the study, further studies with the participation of more centers are needed. Moreover, the mortality rates in the current study might be different to those in other comprehensive studies since almost all patients were immunosuppressive and had underlying diseases.</p><p id="Par30">In conclusion, the results of this study indicates that clinical and environmental <italic>A</italic>. <italic>baumannii</italic> isolates obtained from different centers in Turkey are closely related to each other, the resistance against carbapenems is by far the most important emergency for <italic>A. baumannii</italic> infections and <italic>bla</italic><sub>OXA-23</sub> has become the most prevalent carbapenemase in Turkey.</p></sec></body><back><ack><title>Acknowledgements</title><p>The Acinetobacter Study Group members: <bold>Pinar Zarakolu,</bold> Hacettepe University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey; <bold>Gülden Ersöz,</bold> Mersin University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Mersin, Turkey; <bold>Ali Kaya,</bold> Mersin University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Mersin, Turkey; <bold>Demet Haciseyitoglu,</bold> University of Health Sciences Dr Lutfi Kirdar Education and Research Hospital Department of Medical Microbiology, Istanbul, Turkey; <bold>Öznur Ak,</bold> University of Health Sciences Dr Lutfi Kirdar Education and Research Hospital, Department Infectious Diseases and Clinical Microbiology, Istanbul, Turkey; <bold>Serap Gencer,</bold> University of Health Sciences Dr Lutfi Kirdar Education and Research Hospital, Department Infectious Diseases and Clinical Microbiology, Istanbul, Turkey; Acibadem Mehmet Ali Aydinlar University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey; <bold>Fatma Mutlu Sarigüzel,</bold> Erciyes Üniversity Faculty of Medicine, Department of Medical Microbiology, Kayseri, Turkey; <bold>İlhami Çelik,</bold> Kayseri Education and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Kayseri, Turkey; <bold>Muhammet Hamdullah Uyanik,</bold> Atatürk University, Faculty of Medicine, Department of Medical Microbiology, Erzurum, Turkey; <bold>Kemalettin Özden,</bold> Atatürk University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Erzurum, Turkey; <bold>Ziya Cibali Acikgöz,</bold> Ankara Yildirim Beyazit University Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey; <bold>Rahmet Guner,</bold> Ankara Yildirim Beyazit University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey; <bold>Alper Akcali,</bold> Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Medical Microbiology, Canakkale, Turkey; <bold>Alper Sener,</bold> Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Canakkale, Turkey; <bold>Ali Adiloglu,</bold> Ankara Education and Research Hospital, Department of Medical Microbiology, Ankara, Turkey; <bold>Cemal Bulut,</bold> Ankara Education and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey; Kirikkale University Faculty of Medicine Department of Infectious Diseases and Clinical Microbiology, Kirikkale, Turkey; <bold>Meltem Yalinay,</bold> Gazi University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey; <bold>Murat Dizbay,</bold> Gazi University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey; <bold>Söhret Aydemir,</bold> Ege University, Faculty of Medicine, Department of Medical Microbiology, Izmir, Turkey; <bold>Oguz Resat Sipahi,</bold> Ege University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey.</p></ack><sec sec-type="author-contribution"><title>Authors’ contributions</title><p>BB, and ÖKE designed the project. Acinetobacter Study Group provided the isolates and all hospital data about patients and isolates. BB, ÖKE, ÖU, and RD performed the laboratory experiments. BB, AE, and ÖKE analyzed the data. BB, AE, and ÖKE wrote the paper with input from all authors. ÖKE supervised and coordinated the project. All authors read and approved the final manuscript.</p></sec><sec><title>Funding</title><p>This study was supported by a Hacettepe University Scientific Research Unit (Project no: 011 D07 101 007-135) grant.</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec sec-type="ethics-statement"><sec id="FPar2"><title>Ethics and approval and consent to participate</title><p id="Par32">The Ethics Committee of Hacettepe University approved the study.</p></sec><sec id="FPar3"><title>Consent for publication</title><p id="Par33">Not applicable.</p></sec><sec id="FPar4" sec-type="COI-statement"><title>Competing interests</title><p id="Par34">The authors declare that they have no competing interests.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organisation. Antimicrobial resistance: global report on surveillance. 2014.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peleg</surname><given-names>AY</given-names></name><name><surname>Seifert</surname><given-names>H</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name></person-group><article-title xml:lang="en"><italic>Acinetobacter baumannii</italic>: emergence of a successful pathogen</article-title><source>Clin Microbiol Rev</source><year>2008</year><volume>21</volume><issue>3</issue><fpage>538</fpage><lpage>582</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD1cXpslajs7Y%3D</pub-id><pub-id pub-id-type="doi">10.1128/CMR.00058-07</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname><given-names>MJ</given-names></name><name><surname>Actis</surname><given-names>L</given-names></name><name><surname>Pachon</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en"><italic>Acinetobacter baumannii</italic>: human infections, factors contributing to pathogenesis and animal models</article-title><source>FEMS Microbiol Rev</source><year>2013</year><volume>37</volume><issue>2</issue><fpage>130</fpage><lpage>155</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3sXktF2lurY%3D</pub-id><pub-id pub-id-type="doi">10.1111/j.1574-6976.2012.00344.x</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadimitriou-Olivgeris</surname><given-names>M</given-names></name><name><surname>Fligou</surname><given-names>F</given-names></name><name><surname>Spiliopoulou</surname><given-names>A</given-names></name><name><surname>Koutsileou</surname><given-names>K</given-names></name><name><surname>Kolonitsiou</surname><given-names>F</given-names></name><name><surname>Spyropoulou</surname><given-names>A</given-names></name><name><surname>Zotou</surname><given-names>A</given-names></name><name><surname>Marangos</surname><given-names>M</given-names></name><name><surname>Anastassiou</surname><given-names>ED</given-names></name><name><surname>Christofidou</surname><given-names>M</given-names></name><name><surname>Spiliopoulou</surname><given-names>I</given-names></name></person-group><article-title xml:lang="en">Risk factors and predictors of carbapenem-resistant <italic>Pseudomonas aeruginosa</italic> and <italic>Acinetobacter baumannii</italic> mortality in critically ill bacteraemic patients over a 6-year period (2010–15): antibiotics do matter</article-title><source>J Med Microbiol</source><year>2017</year><volume>66</volume><fpage>1092</fpage><lpage>1101</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1MXps1emtQ%3D%3D</pub-id><pub-id pub-id-type="doi">10.1099/jmm.0.000538</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russotto</surname><given-names>V</given-names></name><name><surname>Cortegiani</surname><given-names>A</given-names></name><name><surname>Graziano</surname><given-names>G</given-names></name><name><surname>Saporito</surname><given-names>L</given-names></name><name><surname>Raineri</surname><given-names>SM</given-names></name><name><surname>Mammina</surname><given-names>C</given-names></name><name><surname>Giarratano</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Bloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteria</article-title><source>Infect Drug Resist</source><year>2015</year><volume>8</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">26300651</pub-id><pub-id pub-id-type="pmcid">4536838</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirel</surname><given-names>L</given-names></name><name><surname>Nordmann</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">Carbapenem resistance in <italic>Acinetobacter baumannii</italic>: mechanisms and epidemiology</article-title><source>Clin Microbiol Infect</source><year>2006</year><volume>12</volume><issue>9</issue><fpage>826</fpage><lpage>836</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD28XhtVeht7bP</pub-id><pub-id pub-id-type="doi">10.1111/j.1469-0691.2006.01456.x</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>D</given-names></name><name><surname>Nielsen</surname><given-names>TB</given-names></name><name><surname>Bonomo</surname><given-names>RA</given-names></name><name><surname>Pantapalangkoor</surname><given-names>P</given-names></name><name><surname>Luna</surname><given-names>B</given-names></name><name><surname>Spellberg</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Clinical and pathophysiological overview of <italic>Acinetobacter</italic> infections: a century of challenges</article-title><source>Clin Microbiol Rev</source><year>2017</year><volume>30</volume><issue>1</issue><fpage>409</fpage><lpage>447</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXht12htrvL</pub-id><pub-id pub-id-type="pmid">27974412</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nigro</surname><given-names>SJ</given-names></name><name><surname>Hall</surname><given-names>RM</given-names></name></person-group><article-title xml:lang="en">Structure and context of <italic>Acinetobacter</italic> transposons carrying the oxa23 carbapenemase gene</article-title><source>J Antimicrob Chemother</source><year>2016</year><volume>71</volume><issue>5</issue><fpage>1135</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv440</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohajeri</surname><given-names>P</given-names></name><name><surname>Farahani</surname><given-names>A</given-names></name><name><surname>Feizabadi</surname><given-names>MM</given-names></name><name><surname>Norozi</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Clonal evolution multidrug resistant <italic>Acinetobacter baumannii</italic> by pulsed-field gel electrophoresis</article-title><source>Indian J Med Microbiol</source><year>2015</year><volume>33</volume><issue>1</issue><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BC2MvjvVyrsA%3D%3D</pub-id><pub-id pub-id-type="doi">10.4103/0255-0857.148390</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Clinical and Laboratory Standards Institute (CLSI)</collab></person-group><source>Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement. CLSI document M100-S24</source><year>2014</year><publisher-loc>Wayne</publisher-loc><publisher-name>CLSI</publisher-name></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Pfizer Inc. (Wyeth Pharmaceuticals): Tygacil<sup>®</sup> Product Insert. Pfizer. 2013. <ext-link xlink:href="http://www.pfizerpro.com" ext-link-type="url">http://www.pfizerpro.com</ext-link>. Accessed 21 May 2017.</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodford</surname><given-names>N</given-names></name><name><surname>Ellington</surname><given-names>MJ</given-names></name><name><surname>Coelho</surname><given-names>JM</given-names></name><name><surname>Turton</surname><given-names>JF</given-names></name><name><surname>Ward</surname><given-names>ME</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Amyes</surname><given-names>SG</given-names></name><name><surname>Livermore</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Multiplex PCR for genes encoding prevalent OXA carbapenemases in <italic>Acinetobacter</italic> spp</article-title><source>Int J Antimicrob Agents</source><year>2006</year><volume>27</volume><issue>4</issue><fpage>351</fpage><lpage>353</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD28Xjs1yiu7c%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2006.01.004</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirel</surname><given-names>L</given-names></name><name><surname>Walsh</surname><given-names>TR</given-names></name><name><surname>Cuvillier</surname><given-names>V</given-names></name><name><surname>Nordmann</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">Multiplex PCR for detection of acquired carbapenemase genes</article-title><source>Diagn Microbiol Infect Dis</source><year>2011</year><volume>70</volume><issue>1</issue><fpage>119</fpage><lpage>123</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXlt1Sgur4%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2010.12.002</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weldhagen</surname><given-names>GF</given-names></name><name><surname>Poirel</surname><given-names>L</given-names></name><name><surname>Nordmann</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">Ambler class A extended-spectrum beta-lactamases in <italic>Pseudomonas aeruginosa</italic>: novel developments and clinical impact</article-title><source>Antimicrob Agents Chemother</source><year>2003</year><volume>47</volume><issue>8</issue><fpage>2385</fpage><lpage>2392</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD3sXlvFCmur4%3D</pub-id><pub-id pub-id-type="doi">10.1128/AAC.47.8.2385-2392.2003</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durmaz</surname><given-names>R</given-names></name><name><surname>Otlu</surname><given-names>B</given-names></name><name><surname>Koksal</surname><given-names>F</given-names></name><name><surname>Hosoglu</surname><given-names>S</given-names></name><name><surname>Ozturk</surname><given-names>R</given-names></name><name><surname>Ersoy</surname><given-names>Y</given-names></name><name><surname>Aktas</surname><given-names>E</given-names></name><name><surname>Gursoy</surname><given-names>NC</given-names></name><name><surname>Caliskan</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">The optimization of a rapid pulsed-field gel electrophoresis protocol for the typing of <italic>Acinetobacter baumannii</italic>, <italic>Escherichia coli</italic> and <italic>Klebsiella</italic> spp</article-title><source>Jpn J Infect Dis.</source><year>2009</year><volume>62</volume><issue>5</issue><fpage>372</fpage><lpage>377</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD1MXhtlCgu7rO</pub-id><pub-id pub-id-type="pmid">19762987</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magiorakos</surname><given-names>AP</given-names></name><name><surname>Srinivasan</surname><given-names>A</given-names></name><name><surname>Carey</surname><given-names>RB</given-names></name><name><surname>Carmeli</surname><given-names>Y</given-names></name><name><surname>Falagas</surname><given-names>ME</given-names></name><name><surname>Giske</surname><given-names>CG</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name><name><surname>Hindler</surname><given-names>JF</given-names></name><name><surname>Kahlmeter</surname><given-names>G</given-names></name><name><surname>Olsson-Liljequist</surname><given-names>B</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name><name><surname>Rice</surname><given-names>LB</given-names></name><name><surname>Stelling</surname><given-names>J</given-names></name><name><surname>Struelens</surname><given-names>MJ</given-names></name><name><surname>Vatopoulos</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>JT</given-names></name><name><surname>Monnet</surname><given-names>DL</given-names></name></person-group><article-title xml:lang="en">Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance</article-title><source>Clin Microbiol Infect</source><year>2012</year><volume>18</volume><issue>3</issue><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38XmvValtb4%3D</pub-id><pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CP</given-names></name><name><surname>Shih</surname><given-names>SC</given-names></name><name><surname>Wang</surname><given-names>NY</given-names></name><name><surname>Wu</surname><given-names>AY</given-names></name><name><surname>Sun</surname><given-names>FJ</given-names></name><name><surname>Chow</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>TL</given-names></name><name><surname>Yan</surname><given-names>TR</given-names></name></person-group><article-title xml:lang="en">Risk factors of mortality in patients with carbapenem-resistant <italic>Acinetobacter baumannii</italic> bacteremia</article-title><source>J Microbiol Immunol Infect</source><year>2016</year><volume>49</volume><issue>6</issue><fpage>934</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2014.10.006</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muntean</surname><given-names>D</given-names></name><name><surname>Licker</surname><given-names>M</given-names></name><name><surname>Horhat</surname><given-names>F</given-names></name><name><surname>Dumitrașcu</surname><given-names>V</given-names></name><name><surname>Săndesc</surname><given-names>D</given-names></name><name><surname>Bedreag</surname><given-names>O</given-names></name><name><surname>Dugăeșescu</surname><given-names>D</given-names></name><name><surname>Coșniță</surname><given-names>DA</given-names></name><name><surname>Krasta</surname><given-names>A</given-names></name><name><surname>Bădițoiu</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Extensively drug-resistant <italic>Acinetobacter baumannii</italic> and <italic>Proteeae</italic> association in a Romanian intensive care unit: risk factors for acquisition</article-title><source>Infect Drug Resist.</source><year>2018</year><volume>8</volume><issue>11</issue><fpage>2187</fpage><lpage>2197</lpage><pub-id pub-id-type="doi">10.2147/IDR.S171288</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Chai</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Bai</surname><given-names>N</given-names></name></person-group><article-title xml:lang="en">Colistin resistance of <italic>Acinetobacter baumannii</italic>: clinical reports, mechanisms and antimicrobial strategies</article-title><source>J Antimicrob Chemother</source><year>2012</year><volume>67</volume><issue>7</issue><fpage>1607</fpage><lpage>1615</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38Xotleqs7k%3D</pub-id><pub-id pub-id-type="doi">10.1093/jac/dks084</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liakopoulos</surname><given-names>A</given-names></name><name><surname>Miriagou</surname><given-names>V</given-names></name><name><surname>Katsifas</surname><given-names>EA</given-names></name><name><surname>Karagouni</surname><given-names>AD</given-names></name><name><surname>Daikos</surname><given-names>GL</given-names></name><name><surname>Tzouvelekis</surname><given-names>LS</given-names></name><name><surname>Petinaki</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">Identification of Oxa-23 producing <italic>Acinetobacter baumannii</italic> in Greece, 2010–2011</article-title><source>Euro Surveill.</source><year>2012</year><volume>17</volume><issue>11</issue><fpage>20117</fpage><pub-id pub-id-type="pmid">22449866</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicek</surname><given-names>AC</given-names></name><name><surname>Saral</surname><given-names>A</given-names></name><name><surname>Iraz</surname><given-names>M</given-names></name><name><surname>Ceylan</surname><given-names>A</given-names></name><name><surname>Duzgun</surname><given-names>AO</given-names></name><name><surname>Peleg</surname><given-names>AY</given-names></name><name><surname>Sandalli</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Oxa and GES-type beta-lactamases predominate in extensively drug resistant <italic>Acinetobacter baumannii</italic> isolates from a Turkish University Hospital</article-title><source>Clin Microbiol Infect</source><year>2014</year><volume>20</volume><issue>5</issue><fpage>410</fpage><lpage>415</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXptVaiu7o%3D</pub-id><pub-id pub-id-type="doi">10.1111/1469-0691.12338</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ergin</surname><given-names>A</given-names></name><name><surname>Hascelik</surname><given-names>G</given-names></name><name><surname>Eser</surname><given-names>OK</given-names></name></person-group><article-title xml:lang="en">Molecular characterization of oxacillinases and genotyping of invasive <italic>Acinetobacter baumannii</italic> isolates using repetetive extragenic palindromic sequence-based polymerase chain reaction in Ankara between 2004 and 2010</article-title><source>Scand J Infect Dis</source><year>2013</year><volume>45</volume><issue>1</issue><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC38XhvVGms7rO</pub-id><pub-id pub-id-type="doi">10.3109/00365548.2012.708782</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asik</surname><given-names>G</given-names></name><name><surname>Ozdemir</surname><given-names>M</given-names></name><name><surname>Kurtoglu</surname><given-names>MG</given-names></name><name><surname>Yagci</surname><given-names>S</given-names></name><name><surname>Oksuz</surname><given-names>L</given-names></name><name><surname>Gul</surname><given-names>M</given-names></name><name><surname>Kocoglu</surname><given-names>ME</given-names></name><name><surname>Sesli Cetin</surname><given-names>E</given-names></name><name><surname>Seyrek</surname><given-names>A</given-names></name><name><surname>Berktas</surname><given-names>M</given-names></name><name><surname>Ayyildiz</surname><given-names>A</given-names></name><name><surname>Ciftci</surname><given-names>AH</given-names></name></person-group><article-title xml:lang="en">Detection of the frequency of PER-1 type extended-spectrum beta-lactamase producing <italic>Acinetobacter baumannii</italic> clinical isolates in Turkey: a multicenter study</article-title><source>Turk J Med Sci.</source><year>2014</year><volume>44</volume><issue>6</issue><fpage>1041</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.3906/sag-1309-126</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cetin</surname><given-names>S</given-names></name><name><surname>Durmaz</surname><given-names>R</given-names></name><name><surname>Tetik</surname><given-names>T</given-names></name><name><surname>Otlu</surname><given-names>B</given-names></name><name><surname>Kaya</surname><given-names>S</given-names></name><name><surname>Çalişkan</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Epidemiologic characterization of nosocomial <italic>Acinetobacter baumannii</italic> infections in a Turkish University hospital by pulsed-field gel electrophoresis</article-title><source>Am J Infect Control</source><year>2009</year><volume>37</volume><issue>1</issue><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.ajic.2008.01.010</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheon</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Yun</surname><given-names>SJ</given-names></name><name><surname>Moon</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title xml:lang="en">Controlling endemic multidrug-resistant <italic>Acinetobacter baumannii</italic> in Intensive Care Units using antimicrobial stewardship and infection control</article-title><source>Korean J Intern Med</source><year>2016</year><volume>31</volume><issue>2</issue><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXmtVSmtrk%3D</pub-id><pub-id pub-id-type="doi">10.3904/kjim.2015.178</pub-id></mixed-citation></ref></ref-list></ref-list><notes notes-type="Misc"><title>Publisher's Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Biochemistry, general</facet-value><facet-value count="1">Biomedicine</facet-value><facet-value count="1">Drug Resistance</facet-value><facet-value count="1">Infectious Diseases</facet-value><facet-value count="1">Medical Microbiology</facet-value><facet-value count="1">Microbial Genetics and Genomics</facet-value><facet-value count="1">Parasitology</facet-value></facet><facet name="keyword"><facet-value count="1">
                Acinetobacter baumannii
              </facet-value><facet-value count="1">Antimicrobial resistance genes</facet-value><facet-value count="1">Clonal relatedness</facet-value><facet-value count="1">Polymerase chain reaction</facet-value><facet-value count="1">Pulsed field gel electrophoresis</facet-value><facet-value count="1">Risk factors</facet-value></facet><facet name="pub"><facet-value count="1">Annals of Clinical Microbiology and Antimicrobials</facet-value></facet><facet name="year"><facet-value count="1">2019</facet-value></facet><facet name="country"><facet-value count="1">Turkey</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
